Log In Sign up
The largest database of trusted experimental protocols

Ruxolitinib

Manufactured by MedKoo Biosciences
Visit Supplier
Sourced in United States

Ruxolitinib is a laboratory reagent used for research purposes. It is a small molecule inhibitor that targets the Janus kinase (JAK) family of enzymes. Ruxolitinib is commonly used in cell-based assays and in vitro studies to investigate the role of JAK signaling pathways in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

2 hydroxypropyl β cyclodextrin, by Merck Group (1 mentions) Lantus solostar, by Sanofi (1 mentions)

2 protocols using ruxolitinib

1

CMML Therapeutic Treatment in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Secondarily transplanted mice with Cblf/f;Cbl-bf/f;CreERT2 mice treated with TAM developed CMML at ∼9 wk. Mice were divided randomly into three groups and treated by oral gavage daily with vehicle, the JAKi Ruxolitinib (60 mg per kilogram body weight), or the FLT3i quizartinib (10 mg per kilogram of body weight). Ruxolitinib was dissolved in PEG300/5% glucose (1:3), while quizartinib (both from Medkoo Biosciences) was dissolved in 5% 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich). At 6 wk, mice were sacrificed for CBC and flow analysis for HSPC and lineage distributions in the BM and spleen.
Lv K., Jiang J., Donaghy R., Riling C.R., Cheng Y., Chandra V., Rozenova K., An W., Mohapatra B.C., Goetz B.T., Pillai V., Han X., Todd E.A., Jeschke G.R., Langdon W.Y., Kumar S., Hexner E.O., Band H, & Tong W. (2017). CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes & Development, 31(10), 1007-1023.
+ Open protocol
+ Expand
2

Evaluation of Novel Therapeutics in Preclinical Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following drugs and chemicals were used: ruxolitinib (Medkoo Biosciences, Morrisville, NC, USA), enalapril maleate (Ezapril, Multi-Apex Pharma, Cairo, Egypt), insulin glargine (Lantus® Solostar® Sanofi Aventis), ketamine (Rotexmedica GmbH, Trittau, Germany), xylazine (xylaject 2%; Adwia, Cairo, Egypt), and strepto-zotocin (TOKU-E, Bellingham, WA, USA).
El-Kady M.M., Naggar R.A., Guimei M., Talaat I.M., Shaker O.G, & Saber-Ayad M. (2021). Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy. Pharmaceuticals, 14(7), 608.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!